The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine...
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Novo Holdings, Novo Nordisk's parent company, is acquiring US contract development and manufacturing organization (CDMO) Catalent for $16.5 billion. The companies said...
Catalent, a US-headquartered CDMO, has broken ground on a project in Schorndorf, Germany, that will add capacity for storing and handling clinical trial supply materials...
Catalent has opened a new commercial-scale cell therapy manufacturing facility at its European center of excellence for cell therapies in Gosselies, Belgium.
US-headquartered CDMO giant Catalent has completed the expansion of its clinical supply facility in the Waigaoqiao Free Trade Zone (FTZ) in Shanghai, China.
Catalent has announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.
CDMO heavyweight Catalent is acquiring compatriot Metrics Contract Services, a full-service specialty CDMO with a facility in Greenville, North Carolina, for $475 million...
